Governments Need Legal Solution as Telemedicine is Here to Stay, says GlobalData
GlobalData releases report on the physician's perspective of telemedicine.
With over three-quarters of US and European healthcare professionals saying they will continue using telemedicine after the COVID-19 crisis ends, governments are under pressure to make telemedicine a standard mode of care. Countries will need to establish consistent and clear legal frameworks for this technology in order to make permanent the temporary changes implemented to support telemedicine during the pandemic, says GlobalData.
GlobalData’s latest report, “Coronavirus Disease 2019 (COVID-19) Case Study: Telemedicine – Physician Perspective”, reveals that 72% of EU physicians were already using telemedicine to assess and treat their patients pre-COVID-19, while the adoption of telemedicine was lagging behind in US with 47% physicians using the technology.
A total of 267 specialists from the US, UK, France, Italy, Spain, Germany and Japan, including gastroenterologists, cardiologists, and pulmonologists, participated in online surveys that were fielded from May 27, 2020 to July 2, 2020.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
